US 7,320,982 B2
Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1
Françoise Bono-Combie, Toulouse (France); Jacqueline Fournier, Plaisance du Touch (France); Jean Marc Herbert, Tournefeuille (France); Isabelle Lamarche, Lara (France); and Umberto Guzzi, Milan (Italy)
Assigned to sanofi-aventis, Paris (France)
Filed on Feb. 05, 2004, as Appl. No. 10/773,073.
Application 10/773073 is a division of application No. 10/044223, filed on Nov. 20, 2001, granted, now 6,693,118.
Application 10/044223 is a division of application No. 09/423884, granted, now 6,342,505, previously published as PCT/FR98/01000, filed on May 20, 1998.
Claims priority of application No. 97 06522 (FR), filed on May 28, 1997.
Prior Publication US 2004/0157868 A1, Aug. 12, 2004
Int. Cl. A61K 31/443 (2006.01); A61K 31/44 (2006.01)
U.S. Cl. 514—277 1 Claim
 
1. A method of inhibiting apoptosis in a patient with prion disease which comprises administering an effective amount of a compound selected from 1-[2-(6,7-methylenedioxynaphth-2-yl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine, 1-[2-(4-cyclohexenylphenyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine and 1-[2-biphenyl-4-yl)ethyl]-4-(2-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or a pharmaceutically acceptable salt thereof.